Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure

This study aimed to evaluate the effectiveness and safety of combining finerenone and empagliflozin in lowering systolic blood pressure (SBP) in patients with chronic kidney disease and type 2 diabetes, particularly examining the differences between combination therapy and monotherapy. The findings indicated that combination therapy significantly improved SBP reduction in participants with baseline SBP ≥130 mm Hg, while the reduction in urinary albumin-to-creatinine ratio was largely independent of early SBP changes. The authors suggest that further research with ambulatory blood pressure monitoring is needed to validate these results.